Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Belimumab to Mobilise Memory B-cells From Secondary Lymhoid Organs to Improve Memory B-cell HLA-specificity Profiling to Support Delisting for Transplant Access in Highly-sensitized

NCT07539857 is registered in ClinicalTrials.gov with Leiden University Medical Center as lead sponsor.

NCT NCT07539857
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07539857 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Belimumab to Mobilise Memory B-cells From Secondary Lymhoid Organs to Improve Memory B-cell HLA-specificity Profiling to Support Delisting for Transplant Access in Highly-sensitized
Lead sponsor
Leiden University Medical Center
Phase
Phase 2
Overall status
Recruiting
Start date
April 1, 2026
Completion date
January 1, 2030
Enrollment
25 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

kidney transplant rejection